Patrick ONeil - Ionis Pharmaceuticals Senior Vice President - Legal, General Counsel
| IONS Stock | USD 42.09 0.50 1.20% |
President
Mr. Patrick R. ONeil is Senior Vice President, Legal, General Counsel, Chief Compliance Officer and Corporationrationrate Secretary of Ionis Pharmaceuticals Inc. MrMr. ONeil also serves as our Chief Compliance Officer and Corporationrationrate Secretary. From September 2010 to January 2013, Mr. ONeil served as our Vice President, Legal and General Counsel and from January 2009 to September 2010, he served as our Vice President, Legal and Senior Transactions Counsel. From October 2001 to January 2009 he held various positions within our Legal department. Prior to joining Ionis, Mr. ONeil was an associate at Cooley LLP. since 2016.
| Age | 44 |
| Tenure | 8 years |
| Address | 2855 Gazelle Court, Carlsbad, CA, United States, 92010 |
| Phone | 760 931 9200 |
| Web | https://www.ionispharma.com |
Ionis Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (0.0751) % which means that it has lost $0.0751 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.7634) %, meaning that it created substantial loss on money invested by shareholders. Ionis Pharmaceuticals' management efficiency ratios could be used to measure how well Ionis Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.13 in 2024. Return On Capital Employed is likely to drop to -0.15 in 2024. At this time, Ionis Pharmaceuticals' Total Assets are comparatively stable compared to the past year. Non Current Assets Total is likely to gain to about 365.6 M in 2024, whereas Intangible Assets are likely to drop slightly above 24.2 M in 2024.Similar Executives
| Showing other executives | PRESIDENT Age | ||
| Harry Leonhardt | Halozyme Therapeutics | 61 | |
| Pushkal Garg | Alnylam Pharmaceuticals | N/A | |
| Richard Ranieri | Biomarin Pharmaceutical | 59 | |
| Gisela Schwab | Exelixis | 61 | |
| Federico Grossi | Apellis Pharmaceuticals | 43 | |
| Zhen Li | Arrowhead Pharmaceuticals | 56 | |
| Guriqbal Basi | Sarepta Therapeutics | 60 | |
| Richard Levy | Incyte | 57 | |
| Alan Eisenberg | Alnylam Pharmaceuticals | N/A | |
| Victoria Brown | Apellis Pharmaceuticals | 44 | |
| Steven Stein | Incyte | 51 | |
| Susan Boynton | Arrowhead Pharmaceuticals | N/A | |
| Masako Nakamura | Alnylam Pharmaceuticals | N/A | |
| Catherine StehmanBreen | Sarepta Therapeutics | 53 | |
| DavidAlexandre Gros | Alnylam Pharmaceuticals | 43 | |
| Catherine Kelleher | Viking Therapeutics | N/A | |
| Gilmore ONeill | Sarepta Therapeutics | 53 | |
| Edward Kaye | Sarepta Therapeutics | 66 | |
| Jing Marantz | Alnylam Pharmaceuticals | N/A | |
| Kevin Fitzgerald | Alnylam Pharmaceuticals | 55 | |
| Vijay Iyengar | Incyte | 45 | |
Management Performance
| Return On Equity | -0.76 | ||||
| Return On Asset | -0.0751 |
Ionis Pharmaceuticals Leadership Team
Elected by the shareholders, the Ionis Pharmaceuticals' board of directors comprises two types of representatives: Ionis Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Ionis. The board's role is to monitor Ionis Pharmaceuticals' management team and ensure that shareholders' interests are well served. Ionis Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Ionis Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Patrick Esq, Chief VP | ||
| Joseph Klein, Independent Director | ||
| Brett Monia, Sr. VP of Drug Discovery and Corporate Devel. | ||
| MA MBA, Executive CFO | ||
| Hayley Soffer, Vice Communications | ||
| Richard Geary, Executive Officer | ||
| Michael Hayden, Director | ||
| Spencer Berthelsen, Independent Director | ||
| Frederick Muto, Independent Director | ||
| Breaux Castleman, Independent Director | ||
| Onaiza CadoretManier, Chief VP | ||
| Peter Reikes, Director | ||
| Patrick ONeil, Senior Vice President - Legal, General Counsel | ||
| Ben Strain, IR Contact Officer | ||
| Lynne Parshall, COO, Corporate Secretary, Director | ||
| Joan Herman, Director | ||
| Dr BSc, Executive Officer | ||
| Joseph Loscalzo, Director | ||
| Eric Swayze, Ex Research | ||
| Joseph Wender, Independent Director | ||
| Wade Walke, Vice President - Corporate Communications | ||
| Sarah Boyce, Chief Business Officer | ||
| Frank Bennett, Senior Vice President - Antisense Research | ||
| JD Esq, Strategic Director | ||
| Damien McDevitt, Chief Business Officer | ||
| Joel Edwards, VP Operations | ||
| Stanley Crooke, Chairman of the Board and Presidentident, CEO | ||
| Elizabeth Hougen, CFO and Sr. VP of Fin. | ||
| Darren Gonzales, Chief VP |
Ionis Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Ionis Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.76 | ||||
| Return On Asset | -0.0751 | ||||
| Profit Margin | (0.47) % | ||||
| Operating Margin | 0.05 % | ||||
| Current Valuation | 5.69 B | ||||
| Shares Outstanding | 145.75 M | ||||
| Shares Owned By Insiders | 0.87 % | ||||
| Shares Owned By Institutions | 99.13 % | ||||
| Number Of Shares Shorted | 9.53 M | ||||
| Price To Earning | 101.16 X |
Ionis Pharmaceuticals Investors Sentiment
The influence of Ionis Pharmaceuticals' investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Ionis. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock market does not have solid backing from leading economists and market statisticians.
Investor biases related to Ionis Pharmaceuticals' public news can be used to forecast risks associated with an investment in Ionis. The trend in average sentiment can be used to explain how an investor holding Ionis can time the market purely based on public headlines and social activities around Ionis Pharmaceuticals. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Ionis Pharmaceuticals' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Ionis Pharmaceuticals' and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average Ionis Pharmaceuticals' news discussions. The higher the estimated score, the more favorable is the investor's outlook on Ionis Pharmaceuticals.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Ionis Pharmaceuticals in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Ionis Pharmaceuticals' short interest history, or implied volatility extrapolated from Ionis Pharmaceuticals options trading.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Ionis Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. For more information on how to buy Ionis Stock please use our How to Invest in Ionis Pharmaceuticals guide.You can also try the Efficient Frontier module to plot and analyze your portfolio and positions against risk-return landscape of the market..
Complementary Tools for Ionis Stock analysis
When running Ionis Pharmaceuticals' price analysis, check to measure Ionis Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Ionis Pharmaceuticals is operating at the current time. Most of Ionis Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Ionis Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Ionis Pharmaceuticals' price. Additionally, you may evaluate how the addition of Ionis Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing |
Is Ionis Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Ionis Pharmaceuticals. If investors know Ionis will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Ionis Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.44) | Earnings Share (2.56) | Revenue Per Share 5.501 | Quarterly Revenue Growth 1.136 | Return On Assets (0.08) |
The market value of Ionis Pharmaceuticals is measured differently than its book value, which is the value of Ionis that is recorded on the company's balance sheet. Investors also form their own opinion of Ionis Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Ionis Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Ionis Pharmaceuticals' market value can be influenced by many factors that don't directly affect Ionis Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Ionis Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Ionis Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Ionis Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.